To update the International Society of Geriatric Oncology (SIOG) 2005 recommendations on geriatric assessment (GA) in older patients with cancer.
INTRODUCTION
More than half of patients newly diagnosed with cancer are age Ն 65 years. 1 Although this number is expected to increase as the world population ages, there is less evidence on which to base treatment decisions for older patients with cancer, because this group is underrepresented in clinical trials. 2 Furthermore, there is heterogeneity in the aging process, which further contributes to the complexity of treatment decisions. These factors contribute to agerelated variations in treatment patterns and outcomes, potentially resulting in increased likelihood of under-or overtreatment, which can influence both risk of treatment toxicity and survival. 3, 4 Because chronologic age alone is a poor descriptor of heterogeneity in the aging process, a systematic and evidence-based way of describing the heterogeneity is needed to guide oncology treatment decisions. A comprehensive geriatric assessment (CGA) can fill this knowledge gap. 5,6 CGA is defined as a multidimensional, interdisciplinary diagnostic process focusing on determining an older person's medical, psychosocial, and functional capabilities to develop a coordinated and integrated plan for treatment and long-term follow-up. 7 In the general (nononcologic) geriatric population, CGA-guided treatment plans have been shown in some, but not all, studies to improve overall survival (OS), quality of life, and physical function and decrease the risk of hospitalization and nursing home placement. 8-10 However, these benefits have primarily been noted in acute geriatric care units. 8, 11 Data on the utility of GA in the older (often ambulatory) cancer population have emerged only more recently. 12 Because CGA research specifically in the oncology setting has mainly studied the diagnostic process/assessment and has not yet thoroughly focused on geriatric interventions, we decided to use the term geriatric assessment (GA) rather than CGA.
The International Society of Geriatric Oncology (SIOG) established recommendations on GA in older patients with cancer in 2005. 13 Numerous publications have emerged during the subsequent years. To synthesize this evidence and provide consensus opinion from individuals with expertise in geriatric oncology, SIOG established four multidisciplinary task forces consisting of individuals with international expertise in CGA in oncology practice. The aim of this article is to synthesize the evidence and provide geriatric oncology consensus on key questions on GA in geriatric oncology: (1) What is the rationale for performing GA? (2) What information is provided by a GA beyond that captured in a standard history and physical exam?
(3) What is the ability of GA to predict oncology treatment-related complications? (4) What is the association between GA findings and OS? (5) What is the impact of GA findings on oncology treatment decisions? (6) What should a GA comprise, including domains and tools? (7) How should GA be organized and implemented in clinical care?
METHODS
A review by Puts et al, 12 relevant to questions 2 to 5, which included published or in-press data through November 16, 2010, was considered as the starting point for our review. Retrieved articles from a systematic literature search by P.H. (Appendix Table A1 , online only, provides detailed information on methodology) were interpreted and discussed by the multidisciplinary group of experts, who could add relevant publications.
A quality score of the retrieved studies was performed by P.H. and C.K. using the methodologic index for nonrandomized studies (Appendix, online only). 14 After a first draft by the writing team, seven expert workgroups (for seven questions) were created (Appendix, online only). For all recommendations, data from the review by Puts et al, 12 as well as the newly selected publications, were used. Table 1 and Appendix Tables A2 to A6 (online only) list the recent publications; the review by Puts et al provided the older data. Finally, a task group consensus was developed. The Oxford 2011 levels of evidence (Appendix Table A7 , online only) were used to grade the quality of evidence and strength of recommendations. 15
RESULTS

Question 1
What is the rationale for performing GA? Key evidence. GA can fill a significant knowledge gap, as described in the Introduction. Many publications have made statements on the rationale for performing GA in older patients with cancer. Key concepts are summarized in the Appendix Table A2 (online only), and most of these concepts are discussed in more detail in the questions 2 to 5 of this article.
Interpretation of key evidence. Important reasons to perform GA in older patients with cancer are: detection of unidentified problems and risks for which targeted interventions can be applied (question 2); prediction of adverse outcomes (eg, toxicity, other relevant items such as functional or cognitive decline, postoperative complications; question 3); and better estimation of residual life expectancy and lethality of the malignancy in the context of competing comorbidities and general health problems (question 4; level 5).
The main goal of GA is to provide a comprehensive health appraisal to guide targeted geriatric interventions and appropriate cancer treatment selection (question 5). GA has the potential to evaluate the balance of benefits and harms of performing or omitting specific oncologic interventions (level 5).
Which patients would benefit from GA is an area of controversy. Many oncologic studies have used age Ն 70 years as the age for implementing GA, but other age cutoffs have been proposed. An active area of research is to identify whether a shorter geriatric screening tool can identify which older patients with cancer would benefit from more comprehensive GA (level 5).
Question 2
What information is provided by a GA beyond that captured in a standard history and physical exam?
Key evidence. The literature from 2010 to 2013 was reviewed to identify research studies summarizing the findings from GA performed in an oncology patient population. A comprehensive review of these study findings is summarized in the Appendix Table A3 (online only). Literature from previous years is summarized in an article by Puts et al. 12 GA identifies age-related problems not typically identified by a routine history and physical examination in approximately half of older patients with cancer. 16, 17 Only one (large) study 15 reported the percentage of patients per domain in whom GA had identified new problems, with the most frequent problems being fatigue (36.6%), nutritional issues (37.6%), and functional impairments (40.1%). Several studies reported only the percentage of patients with at least one deficit, with percentages varying between 90.4% and 92.6%. 24,32 Comparison of the different studies is difficult because of the use of different populations, regions, tools, and cutoffs.
Interpretation of key evidence. Deficits in GA domains are frequent in older patients with cancer (level 3). Assessment of all domains is relevant because GA can potentially identify deficits across domains (level 3). GA reveals deficits that are not routinely captured in a standard history and physical examination (level 3).
Question 3
What is the ability of GA to predict oncology treatmentrelated complications?
Key evidence. GA has the potential to predict several relevant treatment-related complications (eg, postoperative complications, toxicity related to systematic treatment, and so on; Appendix Table  A4 , online only). 12, 19, 25, [39] [40] [41] [42] Because newfound articles on this topic (not discussed in Puts et al 12 review) only focused on severe toxicity (generally defined as grade 3 to 5 adverse events 43 ) related to systemic treatments, we refer to the Puts et al review for predictive capabilities of GA for other outcomes.
Most previously published studies on prediction of chemotherapy toxicity were retrospective, small in size, and underpowered to discover clinically relevant changes. 12 Some studies found no predictive value of GA variables for treatment toxicities, whereas other studies did. Two large prospective studies-CARG (Cancer and Aging Research Group) 20 and CRASH (Chemotherapy Risk Assessment Scale for High-Age Patients) 41 -clearly identified parameters of GA capable of predicting severe chemotherapy-related complications in a heterogeneous cancer population. Both studies attempted to correct for differences in treatment characteristics (CRASH: MAX-2 index; CARG: poly-v monochemotherapy and standard v reduced dose), but these categorizations do not fully capture the diversity of specific chemotherapy drugs and schedules. The predictive ability of these models remains moderate at the individual level, and they require further validation and optimization. Aparicio et al 39 and Falandry et al 42 studied more-homogenous populations of patients with untreated metastatic colorectal cancer and patients with metastatic breast cancer who received first-line chemotherapy, respectively. The specific GA variables predictive for toxicity differed in most studies; however, the factors most consistently associated with toxicity were functional status 12,25,41 and comorbidity. 12 Other identified risk factors were cognitive problems, 12,39,41 lack of social support, 12 hearing difficulties, 20 falls, 20 nutritional status, 41 poor grip strength, 12 and GA group allocation (ie, fit, vulnerable, or frail). 12 Interpretation of key evidence. GA items are predictive (independent from classic oncologic predictors) of the risk of severe treatmentrelated toxicity in a variety of diseases and treatment settings (level 3). The optimal geriatric parameters (including cutoff points) to predict severe treatment toxicity or modify therapeutic approach (including dose or regimen adaptations and/or GA-guided interventions to decrease risk of toxicity) have not yet been established for different cancer types or treatment options (level 4).
Question 4
What is the association between GA findings and OS? Key evidence. There is emerging evidence in the literature regarding the association between factors captured in GA and OS, with several new studies from 2010 to 2013 (Appendix Table A5 , online only). However, a majority of studies were small in size (Ͻ 100 patients) and/or included patients with heterogeneous diseases, treatments, and tumor stages, which could independently have had an impact on overall mortality. Most, but not all, studies identified geriatric parameters that were independent predictors of mortality. 12,22,44-44b Besides age strata, factors most consistently associated with OS were functional status, 12,24,26 nutritional status, 12,24,26,33,34 overall fitness, 12,28,30,31 and mental health. 12, 24, 26 Most studies performed multivariable analyses correcting for some general aspects, but the generally heterogeneous populations in terms of oncologic prognosis (independent of age) were a major weakness. Prognostic models based on GA parameters have been developed in the general geriatric popu-lation (eg, Lee score, 45 Porock scale, 46 and other scales available at the Eprognosis Web site 47 ), allowing prediction of prognosis depending on geriatric parameters at the individual level, but they have not yet been studied specifically within the oncology population. Prognostic indices specifically focusing on older patients with cancer are needed; however, the ideal specificity of these instruments remains unclear. A validated GA for every disease and situation seems impossible to achieve. Because the cancer prognosis competes with other (agerelated) causes of death, distinction between deaths resulting from cancer and other causes should be established whenever possible. 48 Interpretation of key evidence. There is clear evidence that GA items independently predict OS in a variety of oncology diseases and treatment settings (level 4). Poorer OS in older patients with cancer and deficits identified in geriatric domains might potentially be explained by several factors (eg, increased risk of death resulting from causes other than cancer, increased death resulting from cancer because of less aggressive treatment, or death resulting from complications of cancer treatment). Therefore, disease-specific survival and OS should both be reported in trials of older patients with cancer (level 4). Several prognostic models for OS in the general geriatric population are available; however, these have not been specifically validated in older patients with cancer. Prognostic models for geriatric oncology are needed, including both cancer-and geriatric-related prognostic factors (level 4).
Question 5
What is the impact of GA findings on oncology treatment decisions?
Key evidence. We identified six new studies 15,16,23,27,39,49 conducted after 2010 that examined how GA results can affect oncology treatment decisions (Appendix Table A6 , online only). The impact of GA on altering treatment choice varied significantly between the different available studies, ranging from 0% to 83.0%. The GA results more commonly led to a decrease in the aggressiveness of treatments, especially with regard to systemic therapies. It might sometimes be difficult to distinguish the effect of clinical impression (without GA) versus the independent effect of GA on treatment decision. One study 27 compared a treatment recommendation before GA was performed versus treatment recommendations after knowledge of GA results and found that GA did influence oncology treatment decisions (ie, lowering amount of prescribed drugs, reducing chemotherapy intensity, or initiating supportive care) in 44.9% of patients. Decoster et al 49 found that patient age and clinical impression of the physician altered treatment choice in 45% of patient cases, whereas the addition of information provided by GA further changed treatment choice in only 5.0%, including both a decreased intensity of therapy (omission of treatment or dose reduction) as well as an increased intensity of therapy (standard therapy instead of dose reduction). GA also allowed pretreatment patient optimization, when remediable problems were unmasked. 23 Interpretation of key evidence. Age by itself and clinical impression lead to treatment changes in a significant proportion of older patients with cancer, although the appropriateness of this judgment is underdocumented (it might lead to overtreatment or, more frequently, undertreatment) 3,4 (level 4). GA can additionally influence treatment decisions in older patients with cancer, either by decreasing or increasing treatment intensity (level 4). GA can inform key parts of the decision-making process to tailor treatment and trigger targeted GA-driven interventions (level 4). Oncology teams should integrate GA findings into treatment decisions (level 4).
Question 6
What should a GA comprise, including domains and tools? Key evidence. Important domains in a GA are functional status, comorbidity, cognition, mental health status, nutrition, social status and support, fatigue, and assessment for polypharmacy and presence of geriatric syndromes, and various tools are available for assessing these domains. An overview of the different tools that were used in retrieved articles to assess the different domains of a GA in older patients with cancer is provided in Table 1 . Classical oncology tools of functional status assessment like Eastern Cooperative Oncology Group or Karnofsky performance status have been shown to poorly reflect functional impairment in older patients with cancer. 50,51 Nearly all geriatric tools were developed in the general geriatric population and are subsequently being used in the geriatric oncology population. Tools describing polypharmacy and potentially inappropriate medications in older adults (eg, Beers criteria 35 and STOPP [Screening Tool of Older Person's Prescriptions] and START [Screening Tool to Alert Doctors to Right Treatment] criteria 36 ) and sarcopenia 37 as a geriatric syndrome were added to the list of domains and tools because of their high relevance in geriatric care. Assessment of spirituality and religion is also relevant to both geriatric and oncology care. 52 Most oncology teams and research groups use fixed combinations of tools in the original or adapted form; most of these are first-(eg, collection of single-domain, individually validated instruments) and second-generation instruments (eg, GA-introduced, health setting-specific comprehensive assessments). 53 Examples are the European Organisation for Research and Treatment of Cancer minimal data set 54 ; Multidimensional Prognostic Index 55 ; short, primarily selfadministered GA tool developed by the Cancer and Leukemia Group B (Alliance) 19 ; Mini Geriatric Assessment 56 ; and National Comprehensive Cancer Network Senior Adult Oncology Guidelines, 57 which summarize various tools for assessing older patients with cancer. The online InterRAI-tool 58 is a standardized and internationally validated tool for assessing geriatric patients with different levels of clinical complexity across all health care settings (eg, home care, nursing homes, and acute hospitals). However, this more comprehensive tool is time consuming and has not been validated in oncologicy patients.
The InterRAI Consortium 59 is in the process of developing a tool specifically for older patients with cancer.
Interpretation of key evidence. Important domains in GA are functional status, fatigue, comorbidity, cognition, mental health status, social support, nutrition, and geriatric syndromes (eg, dementia, delirium, falls, incontinence, osteoporosis or spontaneous fractures, neglect or abuse, failure to thrive, constipation, polypharmacy, pressure ulcers, and sarcopenia) 19 (level 5). Various tools are available to investigate these domains, and the superiority of one tool over another has not been proven. Choice of instrument might rely on local preference, aim of the tool, or resources present (level 5).
Question 7
How should GA be organized and implemented in clinical care? Key evidence. Table 2 describes major models for implementation of GA in general geriatric medicine and in geriatric oncology, as well as the potential advantages and disadvantages of each approach. Three major models were identified. The first model is the creation of geriatric oncology units 60,66 within selected general oncology hospitals. This has the major advantage that geriatric expertise is centralized; however, the disadvantage is that this model can only reach a limited number of patients who are willing and able to travel to the geriatric oncology unit for consultation. Another model is to bring geriatric consultation teams 15,67 to patients who remain under the supervision of their treating oncologists. This model is possible in settings where oncology clinics are located within general hospitals with physician and multidisciplinary geriatric expertise. There is synergy in the care of this patient population, and therefore, this model has the potential advantage of reaching a large proportion of older patients with cancer. The crosstalk between oncology and geriatric teams allows for crossfertilization of oncology and geriatric principles. Selected patients can also be referred to appropriate specific geriatric programs, such as a geriatric day care center, fall clinic, or memory clinic. The third model occurs in settings where geriatric expertise is not nearby (eg, standalone cancer centers without geriatric department or private practice oncology clinics). In these settings, GA can be performed to identify high-risk patients who could be referred to geriatricians outside of the cancer center (consultation or even electronic consulting 68 ) or to members of a multidisciplinary team within the cancer center. Some comprehensive cancer centers have created nurse practitioner-led clinics to increase accessibility of care in regions with long distances to specialist care and/or long waiting lists resulting from a lack of geriatric staff in general hospitals. 69 Additional research is needed regarding the effectiveness of these models among patients with cancer.
Interpretation of key evidence. There are several ways of implementing GA in geriatric oncology (level 4). All models have advantages and disadvantages (Table 2) , and preference should be given to models that fit with the local health care structure and setting. An assessment of outcomes should be built into the model and reported (level 5). Interaction with multidisciplinary geriatric teams (for selected patients) is highly recommended (level 5).
DISCUSSION
This article summarizes the review and interpretation of key evidence related to GA in geriatric oncology by the SIOG GA task force. We performed quality assessment of included studies. Because no randomized studies were available, and because of inconsistencies among some study results, the levels of evidence supporting the recommendations from this expert consensus panel were generally low.
Nevertheless, abundant information is present demonstrating that GA detects general health care problems in older patients with cancer that routinely are under-recognized in clinical oncology care. However, prevalence rates of geriatric conditions in any population correlate positively with the number of conditions evaluated for and strongly depend on selected tools, cutoffs for defining impairment, and the time points of evaluation. 70 There is general agreement regarding the domains of a GA; however, there are several different tools used to evaluate these domains, making cross-study comparison difficult. Therefore, future research should focus on standardization of assessment tools. Furthermore, there is a need to standardize interventions usng expertise from a multidisciplinary geriatric and oncology team. Performance capacity of various GA tools and the efficacy of interventions in different settings should also be considered. GA results should be docu-mented in patients' medical records so that these results are available when treatment decisions are being made. This will require the development of algorithms for scoring and interpretation of the results for treating physicians. Future research should explore how problems detected by the GA and subsequent interventions interact with cancer care. Specifically, research is needed regarding the optimal way to communicate the information to the clinical team and how referrals for the implementation of GA-guided interventions should be organized.
GA has been shown to predict the risk of treatment-related complications (eg, chemotherapy toxicity or surgical risk), but toxicity prediction at the individual level remains moderate. This is likely because individual treatment toxicity is dependent on a variety of factors, including general host factors (eg, age, genetic predisposition, and capacity for metabolizing drugs), factors identified in a GA (eg, functional status, comorbidity, and others described in our article), treatment-related aspects (eg, choice of Models should be built integrating both biologic and clinical aspects as well as geriatric parameters, which might predict toxicity better than each of these alone. Studies have generally focused on severe toxicity, mostly defined as grade 3 to 5. It should be recognized that specific grade 2 toxicities can also be associated with significant morbidity in older patients with cancer, and these drugspecific adverse effects should also be captured in study designs. 71 The prognostic capacity for survival of existing GA-based models such as Eprognosis 47 should be explored in older cancer populations. Given the major impact of cancer-specific characteristics like tumor type, stage, and treatment, it is preferable to study this in uniform cancer populations where oncologic differences are small. The emerging big data systems combining patient and treatment information from electronic medical records present a unique opportunity for generating these data that should be harnessed. OS and treatment efficacy can also be significantly influenced by tumor biology, independent of the ageing process. For instance, similar tumors treated with identical therapy might respond differently because of differences in drug sensitivity. Personalized medicine for the tumor attempts to find the right drug and treatment for the right tumor, but personalized medicine should also titrate treatment to the host capacity to tolerate treatment. Future models should integrate biologic and GA aspects to further optimize the prognostic models.
Randomized trials comparing GA-guided therapy versus no GA are generally lacking in the oncology field. A fundamental question is whether level I evidence is required for incorporating GA in treatment decision making for older patients with cancer. Is it acceptable to omit GA in clinical trials, knowing that identified problems and subsequent interventions can influence important outcomes independent of treatment, as shown in the geriatric (nononcologic) literature? The effects of GA by itself are limited, unless followed by geriatric interventions, follow-up GA, and adaptation of care planning. 61 Measurement of blood pressure, weight, and blood count have also never been proven in randomized trials to be beneficial, but they are generally considered standard parameters essential for the basic evaluation of patients. Conversely, the geriatric world has been able to perform randomized GA trials and showed outcome benefit, so all efforts in this domain are encouraged. 7,9,11,61-63,71a Because local health care structures and settings can differ, various models for the implementation of GA in geriatric oncology are necessary. Governments should stimulate national or international implementation projects precluding every center from developing its own model. The use of uniform assessment is advised and encouraged, because it would allow benchmarking of patient or hospital data and would also allow transfer of the assessment results to other health care settings, such as primary and residential care. This has the potential for improving continuity of care and creating a uniform language for geriatric care problems and syndromes. 72 Further research also needs to focus on cost effectiveness of GA-directed intervention models in older patients with cancer with regard to key outcomes such as decreasing treatment toxicity, hospitalization, and readmissions.
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For studies published before November 16, 2010, see review by Puts et al. 12 †Some studies have reported geriatric syndromes that overlap with other domains. ‡Data reporting on new detected problems (previously unknown to treating physician). §Patients with at least one comorbidity. Abbreviations: CCI, Charlson comorbidity index; CRC, colorectal cancer; DLBCL, diffuse large B-cell lymphoma; ECOG, Eastern Cooperative Oncology Group; FIGO, International Federation of Obstetricians and Gynecologists; GA, geriatric assessment; GFI, Groningen frailty indicator; GVS, geriatric vulnerability score; HR, hazard ratio; IADL, instrumental activity of daily living; IPI, International Prognostic Index; MNA, Mini Nutritional Assessment; NA, not applicable; NR, not reported; OR, odds ratio; OS, overall survival; PS, performance status; SCS, simplified comorbidity score. When treatment plan was decided before GA (n ϭ 24), it altered final decision in only one patient (4%); for those for whom treatment plan was undecided (pending further investigation and patient decision), findings on GA affected final plan in five patients (83%); only 60% of recommendations made for management of additional problems identified were implemented Abbreviations: ADL, activity of daily living; ECOG, Eastern Cooperative Oncology Group; GA, geriatric assessment; IADL, instrumental activity of daily living; MMSE, Mini Mental State Examination; OR, odds ratio; PS, performance status; SD, standard deviation; ULN, upper limit of normal.
